Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PolyPeptide Group AG ( (CH:PPGN) ) just unveiled an announcement.
Shareholders of PolyPeptide Group AG approved all board proposals at the company’s fifth ordinary Annual General Meeting, with 26,780,855 voting shares represented, or 80.85% of the issued share capital. The strong turnout underscores solid investor engagement as the company advances its role as a specialized CDMO in the peptide-based API market.
All six board members were re-elected, including Peter Wilden as chairman, and the existing compensation and nomination committee members were confirmed for another term. Investors also signed off on 2025 financial statements, non-financial reporting, compensation levels and discharge of directors and executives, signalling broad support for current governance and strategic direction ahead of the next AGM scheduled for 7 April 2027.
The most recent analyst rating on (CH:PPGN) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized global contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients for pharma and biotech customers. Serving a rapidly growing market from preclinical to commercial stages, it targets therapeutic areas such as metabolic diseases, including GLP-1, through a global network of six GMP-certified sites in Europe, the U.S. and India, with shares listed on SIX Swiss Exchange.
Average Trading Volume: 72,614
Technical Sentiment Signal: Buy
Current Market Cap: CHF982.7M
For detailed information about PPGN stock, go to TipRanks’ Stock Analysis page.